Moderna Stock Falls Despite Vaccine Sales More Than Tripling From Last Year

Categories:

/worlds-billionaires, Banking & Insurance, Breaking, breaking-news, ETFs & Mutual Funds, Forbes, healthcare, Hedge Funds & Private Equity, Investing, Markets, News, Policy

May 4, 2022

by Sergei Klebnikov, Forbes Staff

Shares moved lower despite strong earnings results from the vaccine-maker.

Read the full post at Forbes - Healthcare

Vote This Post Down

Vote This Post Up

(No Ratings Yet)

Explore the Archive